Lifecore Biomedical Inc expected to post a loss of 9 cents a share - Earnings Preview

Lifecore Biomedical

05/08/2025 21:38

Lifecore Biomedical Inc LFCR.OQ LFCR.O is expected to  show a fall in quarterly revenue when it reports  results on August 7 for the period ending May 31 2025

The Chaska Minnesota-based  company is expected to report a 6.7% decrease in revenue to $35.363 million from $37.89 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Lifecore Biomedical Inc is for a loss of 9 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Lifecore Biomedical Inc is $10.00, about 25.9% above its last closing price of $7.41

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Feb. 28 2025
-0.15
-0.15
-0.47
Missed
-213.3
Nov. 30 2025
-0.34
-0.29
-0.25
Beat
13.8
Aug. 31 2024
-0.47
-0.46
-0.49
Missed
-5.4​
May. 31 2024
-0.12
-0.12
-0.17
Missed
-41.7
​​Feb. 29 2024
-0.06
Nov. 30 2023
-0.07
​
Aug. 31 2023
-0.26
May. 31 2023
-0.82
-0.37
-0.89
Missed
-137.3

This summary was machine generated August 5 at 20:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)